載入中
NASDAQHealthcareBiotechnology
最新資料
US$13.33
+US$0.63 · +4.96%
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
前收盤價
US$13.33
+US$0.63 · +4.96%
盤中時間採用ET。市場資料可能有所延遲。
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
日內區間
目前US$13.33
52週區間
目前US$13.33
盤中時間採用ET。市場資料可能有所延遲。
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
日內區間
目前US$13.33
52週區間
目前US$13.33
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 8520.9萬 USD | 3.7萬 USD | 2072.3萬 USD | 312.9萬 USD | 1803.8萬 USD |
| 銷貨成本 | 762.5萬 USD | 1.41億 USD | 9709.6萬 USD | 8025.3萬 USD | 6136萬 USD |
| 毛利 | 7758.4萬 USD | −1.41億 USD | −7637.3萬 USD | −7712.4萬 USD | −4332.2萬 USD |
| 研究與開發 | 1.96億 USD | 1.41億 USD | 9709.6萬 USD | 8025.3萬 USD | 6136萬 USD |
| 銷售、一般及管理費用 | 4906萬 USD | 4657.9萬 USD | 3649.4萬 USD | 3290.8萬 USD | 2801.1萬 USD |
| 營業費用 | 2.37億 USD | 4657.9萬 USD | 3649.4萬 USD | 3290.8萬 USD | 2801.1萬 USD |
| 利息收入 | 1947.5萬 USD | 2705萬 USD | 1221.1萬 USD | 257.3萬 USD | 13.7萬 USD |
| 折舊和攤銷 | 762.5萬 USD | 670.5萬 USD | 574.9萬 USD | 388萬 USD | 302萬 USD |
| 營業利益 | −1.6億 USD | −1.88億 USD | −1.13億 USD | −1.1億 USD | −7133.3萬 USD |
| 淨利 | −1.4億 USD | −1.61億 USD | −1.01億 USD | −1.07億 USD | −7131.7萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$29.67
上漲空間 122.58%AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
